Clinical trials: ARDS, Human, open to volunteers
Acute Respiratory Distress Syndrome (ARDS), Pneumonia
Medical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted/Controlled Mechanical Ventilation and Weaning.
Pre-market clinical trial on 81 aldults participants to evidence safety and performance of the non-CE-marked medical device INBENTUS VERSATILE ventilator.
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), Pneumonia, COPD (Chronic Obstructive Pulmonary Disease), Postoperative Respiratory Distress
- Trial name
- NCT07432191
- Testing
- INBENTUS VERSATILE
- Where
- Spain
- Volunteers
- 81 people
- Sponsor
- Iconic Solutions By Murcia SL
Acute Respiratory Distress Syndrome (ARDS)
To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
To evaluate the efficacy, safety and tolerability of STSA-1002 injection in patients with acute respiratory distress syndrome
- Trial name
- NCT07208591
- Testing
- STSA-1002 injection
- Where
- 15 sites in China
- Volunteers
- 406 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Viral Lung Infection and Acute Respiratory Failure
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
- Trial name
- TILIA (NCT05624450)
- Testing
- Tozorakimab
- Where
- 473 sites in United States, Argentina and 37 more
- Volunteers
- 3,527 people
- Sponsor
- AstraZeneca
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Acute Respiratory Distress Syndrome, ARDS
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with…
- Trial name
- NCT05354141
- Testing
- ExoFlo, Intravenous normal saline
- Where
- 32 sites in United States
- Volunteers
- 970 people
- Sponsor
- Direct Biologics, LLC
Acute Respiratory Distress Syndrome
A Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Severe Acute Respiratory Distress Syndrome
Primary Objective: To evaluate the safety and tolerability of human umbilical cord mesenchymal stem cell injection in the treatment of moderate/severe acute respiratory distress syndrome.Secondary Objectives: To explore the…
- Trial name
- ARDS (NCT07413978)
- Testing
- 1 vial containing a total of 5×10^7 cells, 2 vial containing a total of 1×10^8 cells, 3 vial containing a total of 1.5×10^8 cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Changchun Tuohua Pharmaceutical Co., Ltd.
Acute Respiratory Distress Syndrome, Infections
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS…
- Trial name
- NCT05947955
- Testing
- Rhu-pGSN, normal saline
- Where
- 65 sites in United States, Belgium and 11 more
- Volunteers
- 600 people
- Sponsor
- BioAegis Therapeutics Inc.
Lung Cancer Diagnosis
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine…
- Trial name
- PROACT-LUNG (NCT06122077)
- Testing
- blood draw
- Where
- 36 sites in United States
- Volunteers
- 20,000 people
- Sponsor
- Freenome Holdings Inc.
Acute Respiratory Distress Syndrome (ARDS), ARDS
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress…
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT06701656
- Testing
- Cohort C: bevacizumab
- Where
- 41 sites in United States
- Volunteers
- 200 people
- Sponsor
- PPD Development, LP
Acute Respiratory Distress Syndrome
Safety, Tolerability, and Efficacy of MatriPlax in Subjects With Acute Respiratory Distress Syndrome
The goal of this clinical trial is to explore the safety, tolerability, and efficacy in study intervention, MatriPlax, in subjects with Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT05886985
- Testing
- MatriPlax
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- BioSpring Medical Co., Ltd
ARDS (Acute Respiratory Distress Syndrome)
Safety and Efficacy Study of GKL-006RTU in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)
This is a Phase I/II, multicenter study designed to evaluate the safety, tolerability, and preliminary efficacy of GKL-006RTU injection in participants with moderate to severe Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT07706855
- Testing
- GKL-006RTU injection
- Volunteers
- 52 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Acute Respiratory Distress Syndrome, Acute Kidney Injury
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
PrismaLung+ is a sterile, single-use medical device aimed at performing partial removal of carbon dioxide (CO2) from the patient's venous blood via diffusion through a membrane.
- Trial name
- SPARE (NCT07326215)
- Testing
- PrismaLung+, Invasive Mechanical Ventilation
- Where
- 10 sites in China
- Volunteers
- 99 people
- Sponsor
- Vantive Health LLC
Acute Respiratory Distress Syndrome (ARDS)
Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS
Acute respiratory distress syndrome (ARDS) is a life-threatening condition with a diffuse, inflammatory form of lung injury, causing pulmonary infiltration and respiratory failure leading to poor oxygenation.
- Trial name
- NCT05241067
- Testing
- Normal Saline, Centhaquine
- Volunteers
- 80 people
- Sponsor
- Pharmazz, Inc.
Acute Respiratory Distress Syndrome
Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis
This study was conducted to determine the effect of Umbilical Cord Mesenchymal Stem Cell (UC-MSC) and Secretome in severe ARDS patients.
- Trial name
- NCT07439848
- Testing
- Control (NaCl 0.9%), UC-MSC, UC-MSC and Secretome
- Where
- Indonesia
- Volunteers
- 15 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Acute Respiratory Distress Syndrome
To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS).
This study evaluates the safety and potential therapeutic activity of JadiCell™, an investigational umbilical cord-derived mesenchymal stem cell therapy, in patients diagnosed with Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT07479043
- Testing
- Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100 million UC-MSC., Controls will receive two infusions of vehicle solution.
- Volunteers
- 128 people
- Sponsor
- Breathe Biologics, Inc.
ARDS (Acute Respiratory Distress Syndrome)
Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS
This Phase 1/2A, randomized, double-blind study will evaluate the safety, tolerability, and pharmacokinetics (PK) of HT31-1 (hCitH3-mAb) in healthy adult volunteers and in patients with mild-to-moderate acute respiratory distress…
- Trial name
- NCT07449572
- Testing
- HT31-1, Saline (0.9%, sterile, for infusion)
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- HTIC, Inc
Acute Respiratory Distress Syndrome (ARDS), ARDS
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress…
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT06701682
- Testing
- Cohort A: vilobelimab
- Where
- 41 sites in United States
- Volunteers
- 200 people
- Sponsor
- PPD Development, LP
Acute Respiratory Distress Syndrome (ARDS), ARDS
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress…
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT06703073
- Testing
- Cohort A: vilobelimab, Cohort B: paridiprubart, Cohort C: bevacizumab
- Where
- 41 sites in United States
- Volunteers
- 600 people
- Sponsor
- PPD Development, LP
Acute Respiratory Distress Syndrome
Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome (ARDS) is a serious condition where people in hospital care suddenly have trouble breathing because of infection, pneumonia, COVID-19 or other disease.
- Trial name
- NCT06640777
- Testing
- LEAF-4L6715, Supportive Care
- Where
- France
- Volunteers
- 310 people
- Sponsor
- LEAF4Life, Inc.
Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days.
- Conditions
- Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Trial name
- NCT06513949
- Testing
- Atibuclimab
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Implicit Bioscience